AbbVie has returned to the source of its antipsychotic powerhouse Vraylar in search of another blockbuster, paying $25 ...

AbbVie has entered a collaboration with Gedeon Richter (Richter) to develop new treatments for neuropsychiatric conditions.

American Institute for Advanced Investment Management LLP boosted its position in AbbVie Inc. (NYSE:ABBV – Free Report) by ...

AbbVie (ABBV) and Gedeon Richter announced a new discovery, co-development and license agreement to advance novel targets for the potential ...

AbbVie and Gedeon Richter Plc. ('Richter') today announced a new discovery, co-development and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions.

Vyalev, also known as Produodopa, has been approved in 35 countries, with more than 4200 patients having started treatment.

伊利诺伊州北芝加哥 - 艾伯维公司（纽约证券交易所代码：ABBV）和Gedeon Richter Plc.宣布达成协议，共同发现和开发治疗神经精神疾病的新疗法。这项合作建立在近20年的合作伙伴关系基础之上，该合作关系已经产生了中枢神经系统疗法，包括cariprazine（VRAYLAR® / REAGILA®）和研究中的药物ABBV-932。

AbbVie, a global, research-driven biopharmaceutical company, organized a visit to its R&D facilities—the AbbVie Cambridge ...

Half a million people across the UK, of whom I am one, live day in day out with Inflammatory Bowel Disease (IBD). IBD is a ...

Pegasus Park is hosting the upcoming Golden Ticket Pitch Competition, offered by the American Cancer Society’s (ACS) ...

An investigational antibody demonstrated an ability to preserve vision in people with geographic atrophy from dry age-related ...